Overview

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a continuation of a pilot study which is now regarded as a phase II trial with a plan to enroll an additional 40 patients (20 related and 20 unrelated donor transplants) with hematological malignancy assessing the safety and efficacy of a minimally myelosuppressive regimen with pentostatin and low-dose total body irradiation (TBI) followed by allogeneic peripheral blood stem cell transplantation (alloPSCT).
Phase:
Phase 2
Details
Lead Sponsor:
University of Nebraska
Collaborators:
Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.
Treatments:
Cyclosporine
Cyclosporins
Mycophenolate mofetil
Mycophenolic Acid
Pentostatin